RA Capital Nexus Fund III, L.P. — SEC Form 4 filings
SEC reporting owner CIK 1883840. 50 Form 4 filings on record with FilingPulse; latest filed 2026-09-14.
Transaction summary — filings shown
Covers all 50 filings on record, filed 2024-02-14 to 2026-09-14. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 48 legs across 24 filings — 65,699,203 shares, $922,512,220 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 46 legs across 4 filings — 2,033,277 shares, $84,915,966 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 85.
- Largest priced transaction: purchase of 19,728,353 shares @ $20.00 ($394,567,060) in Parabilis Medicines, Inc., filed 2026-06-15.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Parabilis Medicines, Inc. (PBLS) | Director | 3 | 8 legs · 21,433,343 sh · $430,694,551 | — | 7 |
| Artiva Biotherapeutics, Inc. (ARTV) | Director | 14 | 22 legs · 16,975,876 sh · $192,678,449 | — | 14 |
| Septerna, Inc. (SEPN) | Director | 4 | 2 legs · 4,170,000 sh · $75,060,000 | 2 legs · 1,493,000 sh · $63,452,500 | 6 |
| SpyGlass Pharma, Inc. (SGP) | Director | 2 | 2 legs · 3,690,000 sh · $59,040,000 | — | 9 |
| Mineralys Therapeutics, Inc. (MLYS) | Director | 7 | 4 legs · 2,841,766 sh · $56,262,778 | — | 6 |
| Climb Bio, Inc. (CLYM) | Director | 7 | 5 legs · 13,330,218 sh · $50,732,442 | — | 9 |
| Sionna Therapeutics, Inc. (SION) | Director | 6 | 2 legs · 1,125,000 sh · $20,250,000 | 44 legs · 540,277 sh · $21,463,466 | 16 |
| Bicara Therapeutics Inc. (BCAX) | Director | 5 | 3 legs · 2,133,000 sh · $37,794,000 | — | 10 |
| Freenome, Inc. (FRNM) | Director | 1 | — | — | 7 |
| Evommune, Inc. (EVMN) | Director | 1 | — | — | 1 |
Form 4 filings — RA Capital Nexus Fund III, L.P.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-14 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 16,250 (derivative) @ $0 | EDGAR |
| 2026-09-08 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 13,750 (derivative) @ $0 | EDGAR |
| 2026-08-14 | 4 | Septerna, Inc. (SEPN) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Sale (S): 746,500 @ $42.50 · Sale (S): 746,500 @ $42.50 | EDGAR |
| 2026-07-31 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., Kolchinsky Peter, Shah Rajeev M. | Purchase (P): 20,824 @ $9.99 · Purchase (P): 24,944 @ $9.93 | EDGAR |
| 2026-07-28 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., Kolchinsky Peter, Shah Rajeev M. | Purchase (P): 41,319 @ $9.99 | EDGAR |
| 2026-07-23 | 4/A | Artiva Biotherapeutics, Inc. (ARTV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., Kolchinsky Peter, Shah Rajeev M. | Purchase (P): 6,522 @ $8.94 | EDGAR |
| 2026-07-23 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., Kolchinsky Peter, Shah Rajeev M. | Purchase (P): 120,582 @ $9.55 · Purchase (P): 84,124 @ $9.93 · Purchase (P): 59,880 @ $9.96 | EDGAR |
| 2026-07-22 | 4 | Parabilis Medicines, Inc. (PBLS) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Purchase (P): 98,433 @ $27.13 · Purchase (P): 32,987 @ $27.72 · Purchase (P): 21,696 @ $27.96 · Purchase (P): 6,504 @ $29.17 · Purchase (P): 37,723 @ $30 · Purchase (P): 47,250 @ $29.77 | EDGAR |
| 2026-07-22 | 4 | Freenome, Inc. (FRNM) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund II, L.P., Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 6,561,711 · Grant/award (A): 970,950 · Grant/award (A): 553,703 · Grant/award (A): 908,103 · Grant/award (A): 367,427 · Grant/award (A): 4,918,411 @ $10 · +1 more | EDGAR |
| 2026-07-20 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., Kolchinsky Peter, Shah Rajeev M. | Purchase (P): 152,472 @ $8.93 · Purchase (P): 7,882 @ $8.95 | EDGAR |
| 2026-07-14 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., Kolchinsky Peter, Shah Rajeev M. | Purchase (P): 15,102 @ $8.97 · Purchase (P): 6,552 @ $8.94 | EDGAR |
| 2026-07-01 | 4 | Climb Bio, Inc. (CLYM) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund II, L.P., Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 70,284 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Septerna, Inc. (SEPN) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., Kolchinsky Peter, Shah Rajeev M. | Purchase (P): 31,000 @ $8.88 · Purchase (P): 1,876 @ $8.98 | EDGAR |
| 2026-06-18 | 4 | Sionna Therapeutics, Inc. (SION) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 17,340 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., Kolchinsky Peter, Shah Rajeev M. | Purchase (P): 391,019 @ $8.57 · Purchase (P): 15,414 @ $8.99 · Purchase (P): 124,893 @ $8.89 | EDGAR |
| 2026-06-15 | 4 | Parabilis Medicines, Inc. (PBLS) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Conversion (C): 6,556,740 · Conversion (C): 1,187,881 · Purchase (P): 19,728,353 @ $20 · Purchase (P): 1,460,397 @ $20 · Conversion (C): 642,250 (derivative) · Conversion (C): 160,562 (derivative) · +2 more | EDGAR |
| 2026-06-11 | 4 | Parabilis Medicines, Inc. (PBLS) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 20,215 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., Kolchinsky Peter, Shah Rajeev M. | Purchase (P): 479,039 @ $6.91 · Purchase (P): 103 @ $7 · Purchase (P): 548,580 @ $7.91 | EDGAR |
| 2026-06-10 | 4 | Bicara Therapeutics Inc. (BCAX) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 19,475 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Climb Bio, Inc. (CLYM) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund II, L.P., Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2026-05-13 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., Kolchinsky Peter, Shah Rajeev M. | Purchase (P): 6,510,416 @ $11.52 · Purchase (P): 2,170,138 (derivative) @ $11.52 | EDGAR |
| 2026-04-29 | 4 | Climb Bio, Inc. (CLYM) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund II, L.P., Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 2,106,000 (derivative) @ $9.50 | EDGAR |
| 2026-03-31 | 4 | Mineralys Therapeutics, Inc. (MLYS) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Purchase (P): 310,700 @ $23.67 · Purchase (P): 58,300 @ $24.16 | EDGAR |
| 2026-03-02 | 4 | Bicara Therapeutics Inc. (BCAX) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Purchase (P): 300,000 @ $16 · Purchase (P): 2,200,000 (derivative) @ $16.00 | EDGAR |
| 2026-02-20 | 4 | Mineralys Therapeutics, Inc. (MLYS) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 6,200 @ $0 · Grant/award (A): 8,300 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | Evommune, Inc. (EVMN) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 35,868 @ $27.88 | EDGAR |
| 2026-02-11 | 4 | SpyGlass Pharma, Inc. (SGP) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Conversion (C): 2,524,473 · Conversion (C): 1,806,644 · Purchase (P): 3,441,966 @ $16 · Purchase (P): 248,034 @ $16 · Conversion (C): 1,150,941 (derivative) · Conversion (C): 767,294 (derivative) · +4 more | EDGAR |
| 2026-02-09 | 4 | SpyGlass Pharma, Inc. (SGP) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 27,400 (derivative) @ $0 | EDGAR |
| 2026-01-07 | 4 | Climb Bio, Inc. (CLYM) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund II, L.P., Kolchinsky Peter, Shah Rajeev M. | Purchase (P): 7,111 @ $3.50 | EDGAR |
| 2025-12-15 | 4 | Climb Bio, Inc. (CLYM) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund II, L.P., Kolchinsky Peter, Shah Rajeev M. | Disposition to issuer (D): 20,440,000 @ $0 · Purchase (P): 213,099 @ $2.18 · Purchase (P): 101,462 @ $2.86 · Grant/award (A): 20,440,000 (derivative) | EDGAR |
| 2025-11-24 | 4 | Sionna Therapeutics, Inc. (SION) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., Kolchinsky Peter, Shah Rajeev M. | Sale (S): 150 @ $39.89 · Sale (S): 1,235 @ $39.89 · Sale (S): 801 @ $39.89 · Sale (S): 947 @ $39.89 · Sale (S): 96 @ $40.50 · Sale (S): 788 @ $40.50 · +6 more | EDGAR |
| 2025-11-19 | 4 | Sionna Therapeutics, Inc. (SION) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., Kolchinsky Peter, Shah Rajeev M. | Sale (S): 2,182 @ $40.20 · Sale (S): 17,913 @ $40.20 · Sale (S): 11,626 @ $40.20 · Sale (S): 13,734 @ $40.20 · Sale (S): 1,701 @ $41.05 · Sale (S): 13,964 @ $41.05 · +18 more | EDGAR |
| 2025-10-28 | 4 | Sionna Therapeutics, Inc. (SION) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., Kolchinsky Peter, Shah Rajeev M. | Sale (S): 14,116 @ $39.50 · Sale (S): 122,271 @ $39.50 · Sale (S): 66,672 @ $39.50 · Sale (S): 107,941 @ $39.50 · Sale (S): 3,624 @ $39.58 · Sale (S): 31,392 @ $39.58 · +2 more | EDGAR |
| 2025-09-08 | 4 | Mineralys Therapeutics, Inc. (MLYS) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Purchase (P): 1,176,470 @ $25.50 | EDGAR |
| 2025-06-26 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 13,750 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Septerna, Inc. (SEPN) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 16,623 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Sionna Therapeutics, Inc. (SION) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 19,959 (derivative) @ $0 | EDGAR |
| 2025-06-10 | 4 | Bicara Therapeutics Inc. (BCAX) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 23,746 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Climb Bio, Inc. (CLYM) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund II, L.P., Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-03-17 | 4 | Mineralys Therapeutics, Inc. (MLYS) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Purchase (P): 1,296,296 @ $13.50 | EDGAR |
| 2025-02-24 | 4 | Mineralys Therapeutics, Inc. (MLYS) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 32,900 (derivative) @ $0 | EDGAR |
| 2025-02-10 | 4 | Sionna Therapeutics, Inc. (SION) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., Kolchinsky Peter, Shah Rajeev M. | Conversion (C): 5,021,990 · Conversion (C): 527,444 · Conversion (C): 2,222,084 · Conversion (C): 179,975 · Purchase (P): 1,022,586 @ $18 · Purchase (P): 102,414 @ $18 · +10 more | EDGAR |
| 2024-10-30 | 4 | Septerna, Inc. (SEPN) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Conversion (C): 1,695,515 · Conversion (C): 1,130,343 · Purchase (P): 3,828,400 @ $18 · Purchase (P): 341,600 @ $18 · Conversion (C): 14,598,896 (derivative) · Conversion (C): 9,732,596 (derivative) | EDGAR |
| 2024-09-18 | 4 | Bicara Therapeutics Inc. (BCAX) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Conversion (C): 2,622,898 · Conversion (C): 2,500,095 · Purchase (P): 1,680,520 @ $18 · Purchase (P): 152,480 @ $18 · Conversion (C): 18,409,755 (derivative) · Conversion (C): 12,273,169 (derivative) · +2 more | EDGAR |
| 2024-09-16 | 4 | Bicara Therapeutics Inc. (BCAX) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 23,746 (derivative) @ $0 | EDGAR |
| 2024-07-24 | 4 | Artiva Biotherapeutics, Inc. (ARTV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., Kolchinsky Peter, Shah Rajeev M. | Conversion (C): 725,391 · Conversion (C): 264,571 · Conversion (C): 68,320 · Other (J): 323,181 @ $10.20 · Other (J): 138,506 @ $10.20 · Purchase (P): 7,645,007 @ $12 · +6 more | EDGAR |
| 2024-07-01 | 4 | Eliem Therapeutics, Inc. (ELYM) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund II, L.P., Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 973,000 · Grant/award (A): 2,479,872 · Grant/award (A): 1,807,000 · Purchase (P): 11,949,171 @ $3.84 · Purchase (P): 1,059,375 @ $3.84 | EDGAR |
| 2024-05-28 | 4 | Mineralys Therapeutics, Inc. (MLYS) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2024-02-14 | 4 | Mineralys Therapeutics, Inc. (MLYS) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 1,672,508 @ $13.50 · Grant/award (A): 549,755 (derivative) @ $13.50 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1883840 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →